By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Medivir AB 

Lunastigen 7

Huddinge    141 44  Sweden
Phone: 46-8-608-3100 Fax: 46-8-608-3199


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

GlaxoSmithKline (North Carolina) 

Peptimmune, Inc.  Development agreement for inhibitors of Cathepsin S for autoimmune and allergic diseases.





Company News
Medivir (MVRBF) Announces That Janssen Pharmaceutical Has Started A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir On AL-335 Pharmacokinetics 8/3/2015 11:32:57 AM
Medivir (MVRBF) Announces Start Of A Phase I Clinical Trial Of The Nucleotide Polymerase Inhibitor AL-704 For Treatment Of Hepatitis C 7/29/2015 10:28:04 AM
Medivir (MVRBF) Announces That Janssen Submitted Supplemental New Drug Application To U.S. FDA For OLYSIO (Simeprevir) In Combination With Sofosbuvir 7/24/2015 11:07:54 AM
Medivir (MVRBF): OLYSIO Sales During The Second Quarter 2015 7/14/2015 11:58:16 AM
Medivir (MVRBF) Announces The First Cancer Project Derived From Its In-House Nucleotide Platform 6/30/2015 12:07:52 PM
Medivir (MVRBF) Reorganizes and Ditches Neuropathic Pain R&D 6/16/2015 5:57:24 AM
Medivir AB (MVRBF)’s Board Of Directors Has Resolved To Repurchase Own Shares 5/6/2015 9:58:59 AM
Medivir AB (MVRBF): Positive Preclinical Antiviral And Safety Profile Of MIV-802 Supports Continued Development 4/23/2015 8:36:05 AM
Medivir AB (MVRBF): Data From OPTIMIST Trials Show SVR12 Rates Of 97 Percent In HCV Patients Without Cirrhosis And 84 Percent In HCV Patients With Cirrhosis 4/23/2015 6:16:02 AM
Medivir AB (MVRBF) And Cancer Research Technology Collaborate To Develop New Class Of Cancer Drugs 4/13/2015 11:40:26 AM
12345678910...
//-->